Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays

Civil Hospices of Lyon

Status: Completed

Conditions: Peritoneal Mesothelioma

Treatments: Genetic: comparative genomic analysis

Study type: Observational

Funder types: Other

Identifiers

NCT02834234

D50828

Details and patient eligibility

About

Peritoneal mesothelioma is a rare disease representing one third of all mesothelioma and nothing is known about molecular characteristics of this disease. As main cancers, genetic heterogeneity is probable. This genomic profiling associates Comparative Genomic Hybridization (CGH) array, BAP1 sequencing and gene expression in order to discover a biomarker that could be used in the treatment of this rare disease. Corresponding histopathological and immunohistochemical report as all clinical data are available. All data with be merged to underline a few genes of interest on which we will focus our next investigations. Depending of our preliminary results, BAP1 mutations are expected, as it was also described in pleural mesothelioma. Mutations in oncogenic drivers that could be targeted by specific therapy will be on particular interest in management of this rare disease with bad prognosis.

Enrollment: 33 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• surgical biopsy od the peritoneal tumor with frozen samples
• age > 18 years old

Exclusion criteria

• absence of peritoneal mesothelioma
• absence of frozen samples

Trial design

33 participants in 1 patient group

Peritoneal mesothelioma specimens

Description:

The group harbors only patients who received the diagnosis of peritoneal mesothelioma after surgery. All patients are included in this group. The CGH arrays will be realized on frozen samples (for the comparative genomic analysis).

Treatment:

Genetic: comparative genomic analysis